Role Of Prolactin And \( B \)-Hcg In Female Infertility

Ranjit S. Ambad\(^1\), Lata Kanyal Butola\(^2\), Archan Dhok\(^*\), Nandkishor Bankar\(^3\)

\(^1\)Department of Biochemistry Datta Meghe Medical College, Shalinitai Meghe Hospital and Research Centre, Hingana, Nagpur, Maharashtra-441110, India
\(^2\)Department of Biochemistry Jawaharlal Nehru medical, College Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra-442001, India
\(^3\)Department of Microbiology Datta Meghe Medical College, Shalinitai Meghe Hospital and Research Centre, Hingana, Nagpur, Maharashtra-441110, India

**Article History:**
Received on: 22 Oct 2020
Revised on: 10 Nov 2020
Accepted on: 23 Nov 2020

**Keywords:**
Prolactin, female infertility, HCG

**ABSTRACT**
The World Health Organization (WHO) describes infertility as a disability for couples in childbirth to attain pregnancy within 12 months of daily sexual intercourse. The reproductive years of women starts when she starts her menstrual cycle during puberty and capacity to have a child typically ends about age (45) years. However, it may be possible for a woman to become pregnant before her cycles end with menopause. Infertility affects 13–20 per cent of couples worldwide, regardless of race or ethnicity. The present study aim was To study the levels of prolactin and beta hCG in female infertility. And To correlate the levels of prolactin and beta hCG in infertile women and healthy controls. The present study was conducted in the departments of biochemistry and dept. of obstetrics and gynaecology. The study was conducted on two groups of 40 infertile Females and 40 healthy controls. Serum sample used for estimation of prolactin and hCG, assessed by dry chemistry analyzer. Serum prolactin levels in infertile females is 33.96±11.46 and hCG levels was 86.38±12.45, which was higher in infertile female as compared to healthy control with a p-value of<0.05. The present study concludes that Hyperprolactinemia is a major contributing hormonal factor in infertility among infertile women and, as such, prolactin and hCG should be measured in infertile women.

*Corresponding Author
Name: Archan Dhok
Phone: 07218271045
Email: drarchanadhok@gmail.com

ISSN: 0975-7538
DOI: [https://doi.org/10.26452/ijrps.v12i1.4118](https://doi.org/10.26452/ijrps.v12i1.4118)

© 2021 | All rights reserved.

**INTRODUCTION**
The reproductive years of women starts when she starts her menstrual cycle during puberty and capacity to have a child typically ends about age (45) years. However, it may be possible for a woman to become pregnant before her cycles end with menopause (about 51 years of age) (Balen and Rutherford, 2007). Already born girl bears around (400000) immature eggs (oocytes) in her body. These are stored in small, fluid-filled sacs, called follicles, in her ovaries. Upon reaching her reproductive years, she begins to have one egg (or, less generally, more than one) monthly, which can join a male mobile sperm cell during fertilization and become pregnant (Sanders, 2006). The production and release of the egg is largely dependent on hormone balance (chemicals that signal the body organs to perform a particular task). Some of these hormones are produced in the ovaries, while others
are derived from the two brain glands, the hypothalamus and the pituitary (Gronowski et al., 2008). Primary infertility is a term that describes a pair who has never been able to conceive through unprotected sex after a minimum of one year of attempting to do so. Primary infertility causes include a wide array of both physical and emotional factors (Heinonen and Pystynen, 1983). Infertility is called the failure of a couple to achieve conception after one year of unprotected and adequately timed intercourse (regardless of cause) (Eze et al., 2015). It may be primary, i.e. if a couple never conceived following cohabitation and exposure to sexual activity over a two-year span or secondary infertility, i.e. if a couple had previously achieved pregnancy, but frequent unprotected sexual intercourse did not result in a second pregnancy (Wright, 2003). Human infertility is a complicated issue that has various implications depending on the context of society and culture, gender, lifestyle, the sexual history of the people it affects. Infertility is a major problem for public health, partially due to its importance in etiology as well as its difficulty in preventing, diagnosing, and treating it (Wright, 2003). Although some find infertility primarily a woman’s problem, men also contribute to it and are also affected (Audu et al., 2013). Essentially, infertility is graded into two primary infertility and secondary infertility. Predominant infertility in a couple who have never had a child is infertility. Secondary infertility means the inability to conceive following a previous pregnancy. Infertility can be caused by male or female infection, Infertility is often perceived as a predominantly female disorder. However, male-factor infertility is equally prevalent, and half of the infertile couples fail to reproduce due to man fertility problems. Many factors affect its secretion of prolactin, including stress, sleep, pregnancy, food ingestion, and stimulation of the chest wall. Prolactin plays an important role in controlling reproduction. Although its level increase beyond normal (Hyperprolactinemia) can be either physiological, pathological, or idiopathic, its clinical manifestations can vary from extreme to none (Majumdar and Mangal, 2013; Chawla et al., 2012). Endometrial cells were found to have prolactin receptors. Endometrial prolactin secretion helps to preserve endometrial receptivity and has been shown to provide an ideal environment for implanting blastocyst transferred during periods of in-vitro fertilization (IVF). A sufficiently high level of prolactin may inhibit the proliferation of luteinizing granulosa cells. It may also interfere with the function of the corpus luteum resulting in luteal phase defects as well as irregular implantation and embryo growth. Specific studies have shown the presence of a state of Hyperprolactinemia during cycles of IVF / Intracytoplasmic Sperm Injection (ICSI) (Zhong et al., 2012; Boyers et al., 1987). In the early stages of pregnancy, hCG is luteotropic, preserving progesterone development and endometrial support. In maternal semen, hCG can be detected eight days after ovulation (Braunstein et al., 1976) and in blasto- cysts as early as seven days after fertilization (Hay and Lopata, 1988). hCG levels in the maternal blood steadily rise in early pregnancy until peak levels are reached at seven to nine weeks (Kletzky et al., 1985). They progressively decrease until about 20 weeks when plasma levels remain relatively small and steady until the end. Early in pregnancy, there is no link between hCG rates and fetal sex or birthweight. Higher rates of hCG are therefore associated with female fetuses in late pregnancy (Obiekwe and Chard, 1983; Steier et al., 2004).

**Aim And Objective**

**Aim**
To study the levels of prolactin and beta hCG in female infertility.

**Objective**
To correlate the levels of prolactin and beta hCG in infertile women and healthy controls (age-matched) attending AVBRH Wardha and SMHRC Nagpur.

**MATERIALS AND METHODS**

The present study was conducted in the Dept. of Obstetrics and Gynecology and Biochemistry Department at Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi (Meghe) Wardha Maharashtra in collaboration with Datta Meghe Medical College, Shalinitai Meghe Hospital and Research Centre, Nagpur.

Total of 80 subjects were selected for the study, out of which 40 infertile female and 40 age and gender-matched healthy control.

**Sample Collection**
A blood sample was collected, prolactin and beta hCG level was measured in Dry Chemistry Analyzer.

**Inclusion Criteria**
Women with primary and secondary infertility.

**Exclusion Criteria**
1. Urogenital tract anomalies
2. History of thyroid disease/thyroid surgery/thyroid medication.
Table 1: Age Distribution

<table>
<thead>
<tr>
<th>Groups</th>
<th>Number</th>
<th>Age</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases (Infertile Female)</td>
<td>40</td>
<td>31.67±9.05</td>
<td>0.2531</td>
</tr>
<tr>
<td>Control (Fertile Female)</td>
<td>40</td>
<td>29.62±6.70</td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Levels of Prolactin and beta hCG in infertile Female and Healthy control.

<table>
<thead>
<tr>
<th></th>
<th>Infertile Female Mean±SD (n=40)</th>
<th>Healthy Control Mean±SD (n=40)</th>
<th>t Value</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prolactin</td>
<td>33.96±11.46</td>
<td>8.92±2.87</td>
<td>-13.405</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Beta hCG</td>
<td>86.38±12.45</td>
<td>6.6±1.988</td>
<td>-40.021</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

P<0.05

3. Women unwilling to participate or sign informed consent

RESULTS AND DISCUSSION

The above table depicts the age distribution in cases and controls; the mean age in cases is 31.67. In control 29.62, no significant correlation was seen in between cases with a p-value of 0.2531 showed in Table 1.

The levels of Prolactin and beta hCG was increased in infertile female as compared to healthy control. In Infertile females, the levels of prolactin was 33.96±11.46, and in healthy controls, the levels was 8.92±2.87 with a p-value of <0.0001, which a significantly indicating Hyperprolactinemia. Serum beta hCG levels were also increased in infertile women’s with a p-value of <0.0001 showed in Table 2.

The above scatter graph depicts the levels of prolactin in infertile women’s, and normal healthy controls showed in Graph 1.

The above scatter graph depicts the levels of beta hCG in infertile women’s, and normal healthy controls showed in Graph 2.

Human chorionic gonadotropin (hCG), also known as the “pregnancy hormone,” plays a significant role in human reproduction. Serum hCG has a circulating half-life of 24 hours. Female infertility accounts for 37% of all infertile couples, and most of them are attributed to ovulatory dysfunction and are also correlated with dysregulation of the hormonal network (Unuane et al., 2011; Rosato and Garofalo, 2002). The existence of abnormally high prolactin values is considered Hyperprolactinemia, which is one of the most common endocrinological disorders of the hypothalamo-pituitary axis affecting fertility (Ratner et al., 2012; Berinder et al., 2007). Hyperprolactinemia is one of the fertility-influencing endocrinological disorders most severe. The perception that Hyperprolactinemia is not only expressed as galactorrhea and amenorrhea but also induces gonadal dysfunction and infertility has contributed to prolactin estimation in infertile females. Hyperprolactinemia influences the reproductive capacity by impairing pulsatile GnRH secretion and interferes with the function of ovarian-level gonadotropins so as to interfere with ovulation (Poppe and Velkeniers, 2003; Zollner et al., 2001). Hyperprolactinemia triggers galactorrhea together with menstrual and ovulatory disorders. It is present in females with both galactor-
rhea and amenorrhea in two thirds. Thus, serum prolactin levels should be estimated in unexplained infertility, any menstrual abnormalities with or without hirsutism, galactorrhea with or without amenorrhea, luteal phase defects, and anovulation (Valvekar et al., 2016). Mild Hyperprolactinemia may cause infertility even with normal menstruation (Eldin et al., 2013). Women with galactorrhea and Hyperprolactinemia may be predominantly hypothyroidism. Hypothyroidism induces increased TRH secretion that induces thyrotrophin and lactotrophs, causing both TSH & prolactin levels to rise (Valvekar et al., 2016). Hyperprolactinemia decreases the pulsatile release of the GnRH and impairs the secretion of FSH, LH. It also affects ovarian follicle steroidogenic activity and induces insufficient luteal-phase progesterone secretion (Al-Muhammadi et al., 2012). These all result in luteal phase defects, inconstant ovulation, and chronic anovulation. Luteal insufficiency impairs endometrial development and inhibits embryo implantation (Nallusamy and Gracelyn, 2016). It accounts for 3–10 per cent of infertility and two-thirds of these women have Hyperprolactinemia Shibli-Rahhal and Schlechte (2011). In hyperprolactinemic infertility, reduced prolactin secretion with dopaminergic drugs is the best therapy for raising the risk of conception (Crosignani, 2012).

CONCLUSIONS

For nonpregnant people, HCG in the serum rises with age. Consequently, it is concluded that Hyperprolactinemia is a major contributing hormonal factor in infertility among infertile women and, as such, prolactin and hCG should be measured in infertile women. Even with normal menstruation, moderate Hyperprolactinemia can cause infertility. Hyperprolactinemia is one of the most common female infertility endocrinological disorders and is often associated with hypothyroidism. The present study concludes that all infertile women should be offered serum prolactin estimation at an early stage of infertility check-up rather than going for more costly tests or invasive procedures.

Conflict of Interest

The authors declare that they have no conflict of interest for this study.

Funding Support

The authors declare that they have no funding support for this study.

REFERENCES


